Trial Profile
A Prospective, Randomized, Open-label Clinical Trial to Evaluate the Effect of Tektura (Aliskiren), Angiotensin Inhibitors, Diuretics, and Calcium Channel Blockers on Coronary Flow Reserve in Patients With Type II Diabetes and Hypertension.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Amlodipine; Hydrochlorothiazide; Lisinopril
- Indications Hypertension
- Focus Therapeutic Use
- 27 Sep 2017 Status changed from discontinued to withdrawn prior to enrolment.
- 27 Sep 2017 Planned End Date changed from 1 Oct 2012 to 1 Dec 2012.
- 30 Jul 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.